| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Service d'Oncologie médicale, Hôpital Saint-Louis, Paris 75010 [J-M. E., F. R., M. M.]; Institut de Biopharmacie, Rhône-Poulenc Rorer Recherche-Développement, Antony 92165 [R. B.]; Centre Léon Bérard, Lyon 69008 [M. C.]; and Rhône-Poulenc Rorer Recherche-Développement, Antony 92165 [N. Le B.], France
Taxotere (N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyl Taxol; RP 56976; NSC 628503) is a semisynthetic analogue of Taxol. It is twice as active in inhibiting tubuline depolymerization and has a better in vivo activity on B16 melanoma, with responses in advanced colon 38 and PO3 adenocarcinoma. Sixty-five patients (49 women, 16 men), with a median age of 57 years, received 248 courses of Taxotere given as a 1–2-h i.v. infusion every 2 or 3 weeks. Ten distinct dose levels from 5 to 115 mg/m2 were studied. Dose-dependent, reversible neutropenia was the limiting toxicity. Delayed and cumulative skin reactions occurred beyond 70 mg/m2. Alopecia was observed in the majority of patients beyond 70 mg/m2. Four partial responses were achieved in patients with ovarian carcinoma, breast carcinoma, small cell lung cancer, and carcinoma with unknown primary. The pharmacokinetics of Taxotere, determined in 23 patients receiving 20 to 115 mg/m2, was linear. At the highest doses, the Taxotere plasma profile was typically triphasic, with a terminal half-life of 13.5 ± 7.5 (SD) h, a plasma clearance of 21.1 ± 5.3 liters/h/m2, and a distribution volume of 72 ± 40 liters/m2. AUC correlated with the percentage decrease of neutrophils in a sigmoid Emax model. The renal excretion of unchanged Taxotere was very low (<5% of the dose). The recommended dose for phase II trials with this schedule is 100 mg/m2 every 3 weeks.
1 To whom requests for reprints should be addressed, at Service d'Oncologie médicale, Hôpital Saint-Louis, 1, Avenue C. Vellefaux, Paris, 75010, France.
Received 8/ 5/92. Accepted 1/19/93.
This article has been cited by other articles:
|
|
 |
|
  R. G. Maki Gemcitabine and Docetaxel in Metastatic Sarcoma: Past, Present, and Future Oncologist, August 1, 2007; 12(8): 999 - 1006. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hong, S. H. Park, S. J. Choi, S. H. Lee, K. C. Lee, J.-I. Lee, S. Y. Kyung, C. H. An, S. P. Lee, J. W. Park, et al. Nail Toxicity after Treatment with Docetaxel: A Prospective Analysis in Patients with Advanced Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., June 21, 2007; (2007) hym042v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Lee, J. M. Skolnik, and P. C. Adamson Pediatric Phase I Trials in Oncology: An Analysis of Study Conduct Efficiency J. Clin. Oncol., November 20, 2005; 23(33): 8431 - 8441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Pienta and D. C. Smith Advances in Prostate Cancer Chemotherapy: A New Era Begins CA Cancer J Clin, September 1, 2005; 55(5): 300 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Yamamoto, T. Tamura, H. Murakami, T. Shimoyama, H. Nokihara, Y. Ueda, I. Sekine, H. Kunitoh, Y. Ohe, T. Kodama, et al. Randomized Pharmacokinetic and Pharmacodynamic Study of Docetaxel: Dosing Based on Body-Surface Area Compared With Individualized Dosing Based on Cytochrome P450 Activity Estimated Using a Urinary Metabolite of Exogenous Cortisol J. Clin. Oncol., February 20, 2005; 23(6): 1061 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. C. Dees and P. B. Watkins Role of Cytochrome P450 Phenotyping in Cancer Treatment J. Clin. Oncol., February 20, 2005; 23(6): 1053 - 1055. [Full Text] [PDF]
|
|
|
|
|
|
M. Sandstrom, H. Lindman, P. Nygren, E. Lidbrink, J. Bergh, and M.O. Karlsson Model Describing the Relationship Between Pharmacokinetics and Hematologic Toxicity of the Epirubicin-Docetaxel Regimen in Breast Cancer Patients J. Clin. Oncol., January 20, 2005; 23(3): 413 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Minami, Y. Ohe, S. Niho, K. Goto, H. Ohmatsu, K. Kubota, R. Kakinuma, Y. Nishiwaki, H. Nokihara, I. Sekine, et al. Comparison of Pharmacokinetics and Pharmacodynamics of Docetaxel and Cisplatin in Elderly and Non-Elderly Patients: Why Is Toxicity Increased in Elderly Patients? J. Clin. Oncol., July 15, 2004; 22(14): 2901 - 2908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Muro, T. Hamaguchi, A. Ohtsu, N. Boku, K. Chin, I. Hyodo, H. Fujita, W. Takiyama, and T. Ohtsu A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer Ann. Onc., June 1, 2004; 15(6): 955 - 959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. R. Mitchell, R. Basser, M. Chipman, A. Grigg, R. Mansfield, J. Cebon, I. D. Davis, F. Appia, and M. Green A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer Ann. Onc., April 1, 2004; 15(4): 585 - 589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Vasey Role of Docetaxel in the Treatment of Newly Diagnosed Advanced Ovarian Cancer J. Clin. Oncol., May 15, 2003; 21(90100): 136s - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. R. Mitchell, R. Basser, M. Chipman, A. Grigg, J. Cebon, I. D. Davis, J. Zalcberg, S. Ng, F. Appia, and M. Green A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours Ann. Onc., May 1, 2003; 14(5): 788 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ricotti, A. Tesei, F. De Paola, P. Ulivi, G. L. Frassineti, C. Milandri, D. Amadori, and W. Zoli In Vitro Schedule-dependent Interaction between Docetaxel and Gemcitabine in Human Gastric Cancer Cell Lines Clin. Cancer Res., February 1, 2003; 9(2): 900 - 905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Goncalves, F. Viret, J. Ciccolini, D. Genre, G. Gravis, M. Giovanini, J. Camerlo, J. Catalin, D. Maraninchi, and P. Viens Phase I and Pharmacokinetic Study of Escalating Dose of Docetaxel Administered with Granulocyte Colony-stimulating Factor Support in Adult Advanced Solid Tumors Clin. Cancer Res., January 1, 2003; 9(1): 102 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Sessa, C. Cuvier, S. Caldiera, J. Bauer, S. Van den Bosch, C. Monnerat, D. Semiond, D. Perard, A. Lebecq, M. Besenval, et al. Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors Ann. Onc., July 1, 2002; 13(7): 1140 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. S. Glisson, B. A. Murphy, G. Frenette, F. R. Khuri, and A. A. Forastiere Phase II Trial of Docetaxel and Cisplatin Combination Chemotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck J. Clin. Oncol., March 15, 2002; 20(6): 1593 - 1599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C. Zamboni, M. J. Egorin, D. A. Van Echo, R. S. Day, B. R. Meisenberg, S. E. Brooks, L. A. Doyle, N. N. Nemieboka, J. M. Dobson, N. S. Tait, et al. Pharmacokinetic and Pharmacodynamic Study of the Combination of Docetaxel and Topotecan in Patients With Solid Tumors J. Clin. Oncol., September 18, 2000; 18(18): 3288 - 3294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kurata, Y. Shimada, T. Tamura, N. Yamamoto, I. Hyodo, T. Saeki, S. Takashima, K. Fujiwara, H. Wakasugi, and M. Kashimura Phase I and Pharmacokinetic Study of a New Taxoid, RPR 109881A, Given as a 1-Hour Intravenous Infusion in Patients With Advanced Solid Tumors J. Clin. Oncol., September 17, 2000; 18(17): 3164 - 3171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Masuda, S. Negoro, S. Kudoh, T. Sugiura, K. Nakagawa, H. Saka, M. Takada, H. Niitani, and M. Fukuoka Phase I and Pharmacologic Study of Docetaxel and Irinotecan in Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., August 16, 2000; 18(16): 2996 - 3003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Yamamoto, T. Tamura, Y. Kamiya, I. Sekine, H. Kunitoh, and N. Saijo Correlation Between Docetaxel Clearance and Estimated Cytochrome P450 Activity by Urinary Metabolite of Exogenous Cortisol J. Clin. Oncol., June 11, 2000; 18(11): 2301 - 2308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M Kolesar Docetaxel in hepatic impairment Journal of Oncology Pharmacy Practice, June 1, 2000; 6(2): 43 - 49. [Abstract] [PDF]
|
|
|
|
|
|
E. Van Den Neste, Dominique de Valeriola, J. Kerger, H. Bleiberg, Z. Kusenda, C. Brassinne, S. Bartholomeus, J. Selleslags, P. Hennebert, H. Wythouck, et al. A Phase I and Pharmacokinetic Study of Docetaxel Administered in Combination with Continuous Intravenous Infusion of 5-Fluorouracil in Patients with Advanced Solid Tumors Clin. Cancer Res., January 1, 2000; 6(1): 64 - 71. [Abstract] [Full Text]
|
|
|
|
|
|
O. v. Tellingen, J. H. Beijnen, J. Verweij, E. J. Scherrenburg, W. J. Nooijen, and A. Sparreboom Rapid Esterase-sensitive Breakdown of Polysorbate 80 and Its Impact on the Plasma Pharmacokinetics of Docetaxel and Metabolites in Mice Clin. Cancer Res., October 1, 1999; 5(10): 2918 - 2924. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L. Seibel, S. M. Blaney, M. O'Brien, M. Krailo, R. Hutchinson, R. B. Mosher, F. M. Balis, and G. H. Reaman Phase I Trial of Docetaxel with Filgrastim Support in Pediatric Patients with Refractory Solid Tumors: A Collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group Trial Clin. Cancer Res., April 1, 1999; 5(4): 733 - 737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Petrylak, R. B. Macarthur, J. O'Connor, G. Shelton, T. Judge, J. Balog, C. Pfaff, E. Bagiella, D. Heitjan, R. Fine, et al. Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate Cancer J. Clin. Oncol., March 1, 1999; 17(3): 958 - 958. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J Medina, R. S DiPaola, and S. Goodin Treatment of hormone-refractory prostate cancer Journal of Oncology Pharmacy Practice, March 1, 1999; 5(1): 32 - 48. [Abstract] [PDF]
|
|
|
|
|
|
Y. F. Lam, C. J. Chan, and J. G Kuhn Review : Pharmacokinetics and pharmacodynamics of the taxanes Journal of Oncology Pharmacy Practice, June 1, 1997; 3(2): 76 - 93. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
